-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The pharmaceutical and medical sectors performed brightly last Friday, and the market ushered in a rebound
.
Among them, the CRO concept sector performed more prominently.
For example, in terms of individual stocks, Chengda Pharmaceutical’s 20cm daily limit, Medicilon rose by more than 11%, Proton shares rose by more than 9%, Zhaoyan New Drug, Jiuzhou Pharmaceutical and other stocks were among the top gainers
.
Chengda Pharmaceutical Chengda Pharmaceutical is positioned to provide CDMO services for key pharmaceutical intermediates
.
According to public operating performance data, from 2018 to 2020, Chengda Pharmaceutical achieved a year-on-year increase of 0.
58% to 203 million yuan, 44.
69% to 294 million yuan, and 26.
89&.
89% respectively
.
In these three years, the company's net profit increased by 63.
96% year-on-year to 7 million yuan, 708.
10% to 54 million yuan, and 123.
47% to 120 million yuan
.
In the first three quarters of 2021, operating income increased by 8.
58% year-on-year to 290 million yuan; net profit increased by 6.
65% year-on-year to 71 million yuan
.
It is expected that in 2021, operating income will increase by 13.
10%-14.
68% year-on-year, about 420 million to 428 million yuan; net profit will drop by 13.
14% to 15.
04% year-on-year, about 103 million to 105 million yuan
.
Medicilon Medicilon is a CRO listed company with preclinical research as its main business.
As a member of the CRO track, its stock price has risen sharply since its listing in 2019, and reached an all-time high of 800.
01 in September 2021.
Yuan/share, the increase was as high as 1363% during the period, and the market value was as high as 49.
6 billion yuan
.
On February 25, 2022, Medicilon rose 11.
41% to close at 369.
57 yuan
.
According to the 2021 performance report released by Medicilon, the company's operating income in 2021 will increase by 75.
27% year-on-year to 1,167,234,000 yuan; the net profit attributable to owners of the parent company will increase by 117.
93% year on year to 281,977,200 yuan
.
During the reporting period, benefiting from the continuous increase in the encouragement of the state's policies on the pharmaceutical industry and the continuous increase in the investment of pharmaceutical companies in the research and development of innovative drugs, the company firmly grasped the development opportunities of the pre-clinical CRO market, and its customer development capabilities and order acceptance capabilities are synchronized.
boost
.
Proton Co.
, Ltd.
Proton Co.
, Ltd.
is a domestic pharmaceutical contract custom R&D and production enterprise (CDMO).
On February 25, 2022, Proton Co.
, Ltd.
rose 9.
56% to close at 79.
85 yuan
.
It is understood that in 2021, under the background of the stable growth of the global pharmaceutical R&D pipeline and the increasing trend of pharmaceutical R&D and production outsourcing, Proton will continue to expand and enrich its product pipeline, and continue to improve its technical capabilities, product delivery capabilities and order acquisition capabilities.
It is expected that the operating income will increase by 45%-50% compared with the same period last year
.
At the same time, with the further improvement of the company's capacity utilization rate and operational efficiency, as well as the further optimization of the product structure, the profitability of Proton shares has been continuously improved.
It is expected that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2021 will increase by 80%-90% year-on-year
.
Zhaoyan New Drug Zhaoyan New Drug is an early private enterprise engaged in the pharmacology and toxicology evaluation of new drugs in China, and it is also one of the largest institutions engaged in non-clinical safety evaluation services in China.
Other services such as personalized program design, drug screening, pharmacodynamics research, pharmacokinetics research, and safety evaluation of other new chemicals
.
As a representative of the CRO (pharmaceutical R&D contract outsourcing service organization) industry, the operating performance of Zhaoyan New Drug, a listed company, continued to rise sharply
.
According to a recent performance report released by Zhaoyan New Drug, the company's revenue in 2021 will increase by 40.
99% year-on-year to 1.
517 billion yuan; non-net profit will increase by 81.
51% year-on-year to 530 million yuan
.
In addition, the data shows that since its launch in 2017, the performance of Zhaoyan New Drug has maintained stable and rapid development
.
Among them, from 2017 to 2020, Zhaoyan New Drug achieved a year-on-year increase in revenue of 24.
6% to 301 million yuan, 35.
69% to 409 million yuan, 56.
4% to 639 million yuan, and 68.
27% to 1.
076 billion yuan; net profit increased by 47.
89% to 1.
076 billion yuan.
76 million yuan, 41.
72% to 108 million yuan, 72.
39% to 187 million yuan, 68.
67% to 315 million yuan
.
Jiuzhou Pharmaceutical Co.
, Ltd.
is mainly engaged in the research and development, production and sales of chemical raw materials and pharmaceutical intermediates.
.
2021 is a critical year for the company to improve its CDMO platform.
Sufficient capacity reserve + formulation platform extension ensures long-term growth space
.
Since its transformation into CDMO in 2008, Jiuzhou Pharmaceutical has continued to recruit talents and strengthen overseas cooperation, and has grown into a new CDMO player through deep binding with Novartis
.
On February 23, 2022, Jiuzhou Pharmaceutical Co.
, Ltd.
added a new institution to forecast its 2021 annual performance
.
A total of 13 institutions have accumulated in 6 months, and the average net profit in 2021 is predicted to be 641 million yuan, a year-on-year increase of 68.
54%
.
Among them, 11 institutions "buy", 1 institution "prudently increases", and 1 institution "recommends"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, the CRO concept sector performed more prominently.
For example, in terms of individual stocks, Chengda Pharmaceutical’s 20cm daily limit, Medicilon rose by more than 11%, Proton shares rose by more than 9%, Zhaoyan New Drug, Jiuzhou Pharmaceutical and other stocks were among the top gainers
.
Chengda Pharmaceutical Chengda Pharmaceutical is positioned to provide CDMO services for key pharmaceutical intermediates
.
According to public operating performance data, from 2018 to 2020, Chengda Pharmaceutical achieved a year-on-year increase of 0.
58% to 203 million yuan, 44.
69% to 294 million yuan, and 26.
89&.
89% respectively
.
In these three years, the company's net profit increased by 63.
96% year-on-year to 7 million yuan, 708.
10% to 54 million yuan, and 123.
47% to 120 million yuan
.
In the first three quarters of 2021, operating income increased by 8.
58% year-on-year to 290 million yuan; net profit increased by 6.
65% year-on-year to 71 million yuan
.
It is expected that in 2021, operating income will increase by 13.
10%-14.
68% year-on-year, about 420 million to 428 million yuan; net profit will drop by 13.
14% to 15.
04% year-on-year, about 103 million to 105 million yuan
.
Medicilon Medicilon is a CRO listed company with preclinical research as its main business.
As a member of the CRO track, its stock price has risen sharply since its listing in 2019, and reached an all-time high of 800.
01 in September 2021.
Yuan/share, the increase was as high as 1363% during the period, and the market value was as high as 49.
6 billion yuan
.
On February 25, 2022, Medicilon rose 11.
41% to close at 369.
57 yuan
.
According to the 2021 performance report released by Medicilon, the company's operating income in 2021 will increase by 75.
27% year-on-year to 1,167,234,000 yuan; the net profit attributable to owners of the parent company will increase by 117.
93% year on year to 281,977,200 yuan
.
During the reporting period, benefiting from the continuous increase in the encouragement of the state's policies on the pharmaceutical industry and the continuous increase in the investment of pharmaceutical companies in the research and development of innovative drugs, the company firmly grasped the development opportunities of the pre-clinical CRO market, and its customer development capabilities and order acceptance capabilities are synchronized.
boost
.
Proton Co.
, Ltd.
Proton Co.
, Ltd.
is a domestic pharmaceutical contract custom R&D and production enterprise (CDMO).
On February 25, 2022, Proton Co.
, Ltd.
rose 9.
56% to close at 79.
85 yuan
.
It is understood that in 2021, under the background of the stable growth of the global pharmaceutical R&D pipeline and the increasing trend of pharmaceutical R&D and production outsourcing, Proton will continue to expand and enrich its product pipeline, and continue to improve its technical capabilities, product delivery capabilities and order acquisition capabilities.
It is expected that the operating income will increase by 45%-50% compared with the same period last year
.
At the same time, with the further improvement of the company's capacity utilization rate and operational efficiency, as well as the further optimization of the product structure, the profitability of Proton shares has been continuously improved.
It is expected that the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in 2021 will increase by 80%-90% year-on-year
.
Zhaoyan New Drug Zhaoyan New Drug is an early private enterprise engaged in the pharmacology and toxicology evaluation of new drugs in China, and it is also one of the largest institutions engaged in non-clinical safety evaluation services in China.
Other services such as personalized program design, drug screening, pharmacodynamics research, pharmacokinetics research, and safety evaluation of other new chemicals
.
As a representative of the CRO (pharmaceutical R&D contract outsourcing service organization) industry, the operating performance of Zhaoyan New Drug, a listed company, continued to rise sharply
.
According to a recent performance report released by Zhaoyan New Drug, the company's revenue in 2021 will increase by 40.
99% year-on-year to 1.
517 billion yuan; non-net profit will increase by 81.
51% year-on-year to 530 million yuan
.
In addition, the data shows that since its launch in 2017, the performance of Zhaoyan New Drug has maintained stable and rapid development
.
Among them, from 2017 to 2020, Zhaoyan New Drug achieved a year-on-year increase in revenue of 24.
6% to 301 million yuan, 35.
69% to 409 million yuan, 56.
4% to 639 million yuan, and 68.
27% to 1.
076 billion yuan; net profit increased by 47.
89% to 1.
076 billion yuan.
76 million yuan, 41.
72% to 108 million yuan, 72.
39% to 187 million yuan, 68.
67% to 315 million yuan
.
Jiuzhou Pharmaceutical Co.
, Ltd.
is mainly engaged in the research and development, production and sales of chemical raw materials and pharmaceutical intermediates.
.
2021 is a critical year for the company to improve its CDMO platform.
Sufficient capacity reserve + formulation platform extension ensures long-term growth space
.
Since its transformation into CDMO in 2008, Jiuzhou Pharmaceutical has continued to recruit talents and strengthen overseas cooperation, and has grown into a new CDMO player through deep binding with Novartis
.
On February 23, 2022, Jiuzhou Pharmaceutical Co.
, Ltd.
added a new institution to forecast its 2021 annual performance
.
A total of 13 institutions have accumulated in 6 months, and the average net profit in 2021 is predicted to be 641 million yuan, a year-on-year increase of 68.
54%
.
Among them, 11 institutions "buy", 1 institution "prudently increases", and 1 institution "recommends"
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
